Lunit said on the 27th that it has launched an artificial intelligence (AI)-based PD-L1 biomarker analysis solution with Leica Biosystems, a German cancer diagnosis and digital pathology corporations.
PD-L1 is a protein that cancer cells use to evade attacks by immune cells and is considered a key biomarker that determines whether to treat with immunotherapy.
The two companies began collaborating on developing a digital pathology solution in March, and as their first outcome, they unveiled Lunit Scope PD-L1 CAL10, which explores and analyzes the PD-L1 biomarker of Non-small cell lung cancer (NSCLC) for research use.
The solution is optimized for Leica's PD-L1 antibody "CAL10." It can quickly and quantitatively analyze the lung cancer biomarker PD-L1 CAL10, reducing inter-reader variability and helping shorten diagnosis and analysis time while improving consistency.
It is also designed to be used immediately through an integrated workflow linked with Leica's digital pathology scanner "Aperio GT 450."
Karan Arora, senior vice president for advanced analytics, AI and pharmaceutical partnerships at Leica, said, "With this product launch, we can support more seamless biomarker analysis in digital pathology research environments," and added, "Our long-term goal is to help researchers use AI solutions more efficiently."
Seo Beom-seok, chief executive Seo Beom-seok, said, "Through this collaboration, we will continue to expand the potential use of AI-based biomarker solutions in the field of digital pathology research," and "We will strengthen our position in the global digital pathology and precision oncology markets."